Virtual Event: Next Wave of Immune Engagers in Hematological Malignancies

We would like to invite you to a virtual event on state-of-the-art developments in immune cell engagers in hematological malignancies on Tuesday 7th September (15:00 – 18:00 CEST), hosted by Johnson & Johnson Innovation, in collaboration with Janssen Oncology Research & Development. This event will bring together entrepreneurs, start-ups, and academic researchers from across Europe, and beyond, to discuss comprehensive regimens, synergistic combinations and novel targets, all aimed at intercepting disease and moving towards cures for cancer.

You will have the opportunity to hear from a range of key opinion leaders, including Yusri Elsayed, VP Hematologic Malignancies Disease Area Stronghold Leader, Janssen R&D, who will be giving a keynote on the Janssen oncology innovation mission, and a panel discussion between other experts in the area. There will also be an opportunity to hear how Johnson & Johnson Innovation collaborates externally with innovators and scientists.

To view the agenda and register, please click here.